Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):458-9. doi: 10.1016/j.ijrobp.2013.06.2039.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy
  • Carcinoma, Pancreatic Ductal / genetics*
  • Carcinoma, Pancreatic Ductal / mortality
  • Carcinoma, Pancreatic Ductal / therapy
  • Chemoradiotherapy, Adjuvant
  • Combined Modality Therapy / methods
  • Erlotinib Hydrochloride
  • Humans
  • Neoplasm Recurrence, Local / mortality
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / therapy
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use
  • Smad4 Protein / genetics*
  • Smad4 Protein / metabolism
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • SMAD4 protein, human
  • Smad4 Protein
  • Erlotinib Hydrochloride